Study Summary
Gene transfer is a process in which the DNA (genetic material) of certain cells is changed. In this study, gene transfer will be performed on a type of white blood cell (called T cells) to recognize leukemia cells in the same person the T cells were collected from. The goal of this clinical research study is to learn if it is safe to give these genetically-changed T cells back to patients with CLL/SLL. Researchers also want to learn if these cells can help to attack CLL/SLL cells.
Want to learn more about this trial?
Request More InfoInterventions
ROR1R-CAR-T Cell InfusionPROCEDURE
Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.
Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort.
FludarabineDRUG
FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.
FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3.
CyclophosphamideDRUG
FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
RituximabDRUG
FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.
BR Regimen: 375-500 mg/m2 by vein on Day -4.
BendamustineDRUG
BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.
FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3.
Study Locations
No locations listed.